Jin Woo Oh

Jin Woo Oh

Auto-generated profile, based on publicly available information

Jin Woo Oh

Lunit, Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2024 in Nature Methods
Verified
Journal Article
Open access
PDF file
DYDavid Yao
David Yao
JTJosh Tycko
Josh Tycko
JOJin Woo Oh
Jin Woo Oh
LBLexi R. Bounds
Lexi R. Bounds
SGSager J. Gosai
Sager J. Gosai
SRSteven K. Reilly
Steven K. Reilly
The ENCODE Consortium’s efforts to annotate noncoding cis-regulatory elements (CREs) have advanced our understanding of gene regulatory landscapes. Pooled, noncoding CRISPR screens offer a systematic approach to investigate cis-regulatory mechanisms. The ENCODE4 Functional Characterization Centers conducted 108 screens in human cell lines, comprising >540,000 perturbations across 24.85 megabases of the genome. Using 332 functionally confirmed CRE–gene links in K562 cells, we established guidelines for screening endogenous noncoding elements with CRISPR interference (CRISPRi), including accurate detection of CREs that exhibit variable, often low, transcriptional effects. Benchmarking five screen analysis tools, we find that CASA produces the most conservative CRE calls and is robust to artifacts of low-specificity single guide RNAs. We uncover a subtle DNA strand bias for CRISPRi in transcribed regions with implications for screen design and analysis. Together, we provide an accessible data resource, predesigned single guide RNAs for targeting 3,275,697 ENCODE SCREEN candidate CREs with CRISPRi and screening guidelines to accelerate functional characterization of the noncoding genome.

24 July 2023 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
RLRenhe Luo
Renhe Luo
JYJielin Yan
Jielin Yan
JOJin Woo Oh
Jin Woo Oh
WXWang Xi
Wang Xi
DSDustin Shigaki
Dustin Shigaki
MBMichael Beer
Michael Beer

18 February 2026 in Nature
Verified
Journal Article
Open access
PDF file
JBJozef P. Bossowski
Jozef P. Bossowski
RPRay Pillai
Ray Pillai
JKJohn Kilian
John Kilian
ALAngela Wong Lau
Angela Wong Lau
MNMari Nakamura
Mari Nakamura
TPThales Papagiannakopoulos
Thales Papagiannakopoulos
Cancer cells activate the integrated stress response (ISR) to adapt to stress and resist therapy1. ISR signals converge on activating transcription factor 4 (ATF4), which controls cell-intrinsic transcriptional programs that are involved in metabolic adaptation, survival and growth2,3. However, whether the ISR–ATF4 axis influences anti-tumour immune responses remains mostly unknown. Here we show that loss of ATF4 decreases tumour progression considerably in immunocompetent mice, but not in immunocompromised ones, by enhancing T cell-dependent anti-cancer immune responses. An unbiased genetic screen of ATF4-regulated genes identifies lipocalin 2 (LCN2) as the principal ATF4-dependent effector that impairs anti-tumour immunity by favouring infiltration with immunosuppressive interstitial macrophages. Furthermore, we find that LCN2 promotes T cell exclusion and immune evasion in preclinical mouse models, and correlates with decreased T cell infiltration in patients with lung and pancreatic adenocarcinomas. Anti-LCN2 antibodies promote robust anti-tumour T cell responses in mouse models of aggressive solid tumours. Our study shows that the ATF4–LCN2 axis has a cell-extrinsic role in suppressing anti-cancer immunity, and could pave the way for an immunotherapy approach that targets LCN2.

31 October 2025 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
YBYeong Hak Bang
Yeong Hak Bang
GPGeun-Ho Park
Geun-Ho Park
JOJin Woo Oh
Jin Woo Oh
SHSoohyun Hwang
Soohyun Hwang
JJJun-Gi Jeong
Jun-Gi Jeong
SKSe Hoon Kim
Se Hoon Kim
Purpose: This study evaluated the dynamic changes in the tumor microenvironment (TME) in patients with non-small cell lung cancer (NSCLC) and acquired resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) using an artificial intelligence (AI)-powered spatial TME analyzer. We then assessed the predictive efficacy of immune-checkpoint inhibitors (ICIs)-based treatment. Experimental design: An AI-powered whole-slide image analyzer was used to segment cancer areas (CAs) and cancer stroma and to identify tumor-infiltrating lymphocytes (TILs), tertiary lymphoid structures, fibroblasts, and endothelial cells (ECs) in the tumor tissue. We analyzed 143 NSCLC samples after resistance to EGFR-TKIs from two cohorts: (1) 89 patients treated with ICI monotherapy and (2) 54 patients from the ATTLAS phase III trial comparing atezolizumab plus bevacizumab, paclitaxel, and carboplatin (ABCP) versus pemetrexed plus carboplatin. Results: Post-TKI samples showed reduced TILs in the CA (p=0.045) and increased ECs in the CA (p=0.005) compared with pre-TKI samples. These changes differed according to EGFR mutation subtype. Higher TILs in CA were associated with a better overall response rate (ORR) and progression-free survival (PFS). Similarly, higher EC levels in CA correlated with improved ORR and PFS. In the ATTLAS cohort, these factors were associated with clinical benefits from ABCP, with a significant association with TILs and a marginal association with ECs. Conclusion: Our findings suggest that EGFR-TKIs affect the immune landscape of patients with EGFR-mutated NSCLC. Higher TILs or ECs in the CA were significantly associated with a favorable response to subsequent ICI-based treatment. Trial registration number: NCT03991403 .

22 December 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
DYDavid Yao
David Yao
JTJosh Tycko
Josh Tycko
JOJin Woo Oh
Jin Woo Oh
LBLexi R. Bounds
Lexi R. Bounds
SGSager J. Gosai
Sager J. Gosai
SRSteven K. Reilly
Steven K. Reilly
The ENCODE Consortium’s efforts to annotate non-coding, cis -regulatory elements (CREs) have advanced our understanding of gene regulatory landscapes which play a major role in health and disease. Pooled, non-coding CRISPR screens are a promising approach for systematically investigating gene regulatory mechanisms. Here, the ENCODE Functional Characterization Centers report 109 screens comprising 346,970 individual perturbations across 13.3Mb of the genome, using a variety of methods, readouts, and statistical analyses. Across 332 functionally confirmed CRE-gene links, we identify principles for screening endogenous, non-coding elements for causal regulatory mechanisms. Nearly all CREs show strong evidence of open chromatin, and targeting accessibility peak summits is a critical component of our proposed sgRNA design rules. We provide experimental guidelines to accurately detect CREs with variable, often low, transcriptional effects. We discover a previously undescribed DNA strand-bias for CRISPRi in transcribed regions with implications for screen design and analysis. Benchmarking five screen analysis tools, we find CASA produces the most conservative CRE calls and is robust to artifacts of low-specificity sgRNAs. Together, we provide an accessible data resource, predesigned sgRNAs targeting 3,275,697 ENCODE SCREEN candidate CREs, and screening guidelines to accelerate functional characterization of the non-coding genome.

6 October 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
JOJin Woo Oh
Jin Woo Oh
MBMichael Beer
Michael Beer
Gene regulatory elements drive many complex biological phenomena such as fetal development, and their mutations are linked to a multitude of common human diseases. The phenotypic impacts of regulatory variants are often tested using their conserved orthologous counterparts in model organisms such as mice. However, mapping human enhancers to conserved elements in mice remains a challenge, due to both rapid evolution of enhancers and limitations of current computational methods to detect conserved regulatory sequences. To improve upon existing computational methods and to better understand the sources of this apparent regulatory divergence, we comprehensively measured the evolutionary dynamics of distal enhancers across 45 matched human/mouse cell/tissue pairs from more than 1,000 DNase-seq experiments. Using this expansive dataset, we show that while cell-specific regulatory vocabulary is conserved, enhancers evolve more rapidly than other genomic elements such as promoters and CTCF binding sites. We observed surprisingly high levels of cell-specific variability in enhancer conservation rates, in part explainable by tissue specific transposable element activity. To improve orthologous enhancer mapping, we developed an improved genome alignment algorithm using gapped-kmer sequence features, and using the matched cell/tissue pairs, we show that this novel computational method, gkm-align , discovers 23,660 novel human/mouse conserved enhancers missed by standard alignment algorithms.